Loading...
XSTO
CMOTEC B
Market cap9mUSD
Dec 05, Last price  
3.73SEK
1D
0.81%
1Q
8.12%
Jan 2017
-92.96%
IPO
-92.42%
Name

Scandinavian ChemoTech AB

Chart & Performance

D1W1MN
XSTO:CMOTEC B chart
P/E
P/S
13.24
EPS
Div Yield, %
Shrs. gr., 5y
41.51%
Rev. gr., 5y
63.85%
Revenues
7m
+132.67%
0013,8942,084,36327,243560,000556,000131,00049,000473,0002,822,0006,566,000
Net income
-14m
L-34.96%
-7,459-28,137-1,180,834-8,139,023-8,331,608-4,797,000-12,585,000-12,499,000-18,418,000-24,580,000-21,091,000-13,717,000
CFO
-13m
L-27.88%
0-40,907-474,990-7,516,783-14,973,961-4,579,000-11,226,000-8,494,000-19,183,000-19,630,000-18,226,000-13,145,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.
IPO date
Dec 06, 2016
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT